Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

TOP - May 2014, Vol 7, No 2 - Genitourinary Cancers
Alice Goodman

Immunotherapy with ipilimumab improved progression-free survival (PFS) and prostate-specific antigen response compared with placebo, but improvement in overall survival (OS) failed to reach statistical significance in postdocetaxel metastatic castration-resistant prostate cancer (mCRPC). These results of a randomized phase 3 trial (CA184-043) were presented at the 2014 Genitourinary Cancers Symposium.

Although the failure to significantly improve survival is disappointing, the study provided hints of subsets of patients who might derive greater benefit from ipilimumab: patients with more favorable prognostic factors (ie, no visceral metastasis, lower levels of alkaline phosphatase, and elevated hemoglobin).

“Results of this trial support further investigation of ipilimumab in patients with fewer adverse prognostic features than those enrolled in this trial,” said lead author Charles G. Drake, MD, PhD, of the Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland.

CA184-043 enrolled 799 patients with mCRPC who had received docetaxel therapy. After being treated with at least 1 dose of bone-directed radiotherapy, patients were randomized in a 1:1 ratio to ipilimumab versus placebo. During the maintenance phase, those in the ipilimumab arm received ipilimumab every 12 weeks, and those in the placebo arm received placebo every 12 weeks. Median OS was 11.2 months for ipilimumab versus 10 months for placebo (hazard ratio [HR] 0.85; 95% confidence interval [CI], 0.72-1.00; P = .0530).

The secondary end point of PFS was met, Drake reported. Median PFS was 4 months in the ipilimumab group and 3 months in the placebo group.

In a prespecified subset analysis, the presence of visceral metastases appeared to interfere with the treatment effect of ipilimumab. Drake explained that most clinical trials exclude patients with visceral metastases, but this trial did not.

Multivariate analysis identified the following favorable prognostic factors for OS: age <70 years, alkaline phosphatase <1.5 times the upper limit of normal, hemoglobin >11 g/dL, and absence of visceral metastases. Median OS was 14.4 months with ipilimumab in patients with no visceral metastases versus 5.7 months in the presence of visceral metastases.

Drake acknowledged that the trial was underpowered to show an interaction between ipilimumab and visceral metastases, “but the hazard ratio is clearly in the wrong direction.” HR was 1.644 (95% CI, 1.157-2.336) and P = .0056.

The safety of ipilimumab in this study was similar to the experience with ipilimumab in metastatic melanoma, an indication for which it has received approval from the US Food and Drug Administration.

Based on the findings of CA184-043, a separate phase 3 trial of ipilimumab has been launched (CA184-095) in chemotherapy-naive mCRPC patients without visceral metastases.

Reference
Drake CG, Kwon ED, Fizazi K, et al. Results of subset analyses on overall survival (OS) from study CA184-043: ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2014;32(suppl 4): Abstract 2. Presented at: 2014 Genitourinary Cancers Symposium; January 30-February 1, 2014; San Francisco, CA.

Related Items
Adjuvant Chemotherapy in Upper-Tract Urothelial Cancer Shows Impressive Gains in the POUT Trial
Phoebe Starr
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Genitourinary Cancers
Mounting Evidence for Ki67 as Independent Prognostic Marker
Alice Goodman
TOP - February 2017, Vol 10, No 1 published on February 1, 2017 in Breast Cancer
Toxicities Associated with Targeted Therapy and Immunotherapy Underreported in Published Studies
Alice Goodman
TOP - February 2017, Vol 10, No 1 published on February 1, 2017 in Supportive Care
Cognition and Depression Impact Adherence in Elderly Patients Taking Oral Anticancer Drugs
Alice Goodman
TOP - February 2017, Vol 10, No 1 published on February 1, 2017 in Supportive Care
Quality of Life with Hypofractionated Radiotherapy in Patients with Low-Risk Prostate Cancer
Alice Goodman
TOP - November 2016, Vol 9, No 4 published on November 4, 2016 in Conference Correspondent
Doxepin and Magic Mouthwash Effective for Radiation-Induced Oral Mucositis Pain
Alice Goodman
TOP - November 2016, Vol 9, No 4 published on November 4, 2016 in Conference Correspondent
Fewer Adverse Events with Intensity-Modulated Radiation Therapy for Patients with Gynecologic Cancers
Alice Goodman
TOP - November 2016, Vol 9, No 4 published on November 4, 2016 in Conference Correspondent
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
Wayne Kuznar
TOP - August 2016, Vol 9, No 3 published on August 3, 2016 in Genitourinary Cancers
Reassuring Practice Patterns in the Use of Curative Treatment for Men with Prostate Cancer
Phoebe Starr
TOP - May 2016, Vol 9, No 2 published on May 13, 2016 in Genitourinary Cancers
Increased Physical Activity May Help Extend Survival After Prostate Cancer Diagnosis
Charles Bankhead
TOP - May 2016, Vol 9, No 2 published on May 13, 2016 in Genitourinary Cancers
Last modified: September 9, 2019